{"id":"W4399481603","doi":"10.1200/jco.2024.42.16_suppl.7056","title":"A phase 1/2 study of favezelimab in combination with pembrolizumab for heavily pretreated anti–PD-1–refractory classical Hodgkin lymphoma (cHL): An updated analysis.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Medicine; Pembrolizumab; Refractory (planetary science); Classical Hodgkin lymphoma; Oncology; Lymphoma; Internal medicine; Brentuximab vedotin; Cancer research; Hodgkin lymphoma; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003385914,0.001030979,0.001680557,0.0007257872,0.0002584991,0.001196452,0.0006475069,0.0007505997,0.003601674],"category_scores_gemma":[0.001970893,0.0005335583,0.002297003,0.0008337223,0.0003037129,0.0007935752,0.0004322487,0.001282873,0.0006795906],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001028963,"about_ca_system_score_gemma":0.001523048,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001300594,"about_ca_topic_score_gemma":0.004313301,"domain_scores_codex":[0.9990915,0.000417238,0.00007235547,0.0001701052,0.0001508056,0.00009795961],"domain_scores_gemma":[0.9989188,0.0002236553,0.000344653,0.0001106778,0.0001221515,0.0002801192],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5577171,0.01312202,0.07326535,0.005327506,0.03118159,0.0007614275,0.0003901233,0.003226857,0.0338248,0.0003667306,0.01230227,0.2685142],"study_design_scores_gemma":[0.4641516,0.1786664,0.2580853,0.0007245326,0.03776708,0.002524439,0.0002053381,0.002397952,0.004852428,0.0006225257,0.04982343,0.0001789879],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9418942,0.03262489,0.001717449,0.0006922116,0.0002518765,0.005929058,0.01231474,0.0001838173,0.004391767],"genre_scores_gemma":[0.9518002,0.01564403,0.003272718,0.001730011,0.0002303999,0.003219405,0.02111099,0.00008055267,0.00291174],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003601674,"threshold_uncertainty_score":0.01790667,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08561850792821196,"score_gpt":0.4751666784907593,"score_spread":0.3895481705625473,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}